Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Lifted by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,254 shares of the medical research company’s stock after purchasing an additional 42 shares during the period. Quotient Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $776,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. SS&H Financial Advisors Inc. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $205,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $210,000. Mountain Pacific Investment Advisers LLC boosted its position in shares of Thermo Fisher Scientific by 3.1% in the 3rd quarter. Mountain Pacific Investment Advisers LLC now owns 41,758 shares of the medical research company’s stock valued at $25,830,000 after purchasing an additional 1,253 shares during the period. Sanibel Captiva Trust Company Inc. boosted its holdings in shares of Thermo Fisher Scientific by 4.0% in the third quarter. Sanibel Captiva Trust Company Inc. now owns 1,836 shares of the medical research company’s stock worth $1,136,000 after buying an additional 70 shares during the period. Finally, Wedmont Private Capital grew its position in Thermo Fisher Scientific by 14.2% during the 3rd quarter. Wedmont Private Capital now owns 2,338 shares of the medical research company’s stock worth $1,400,000 after purchasing an additional 291 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TMO shares. Stifel Nicolaus raised their target price on Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Stephens initiated coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. TD Cowen raised their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Finally, Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $653.72.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,548,375.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 in the last 90 days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $5.06 during trading on Thursday, reaching $594.19. The stock had a trading volume of 319,869 shares, compared to its average volume of 1,462,149. The stock has a fifty day simple moving average of $608.66 and a two-hundred day simple moving average of $583.10. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88. The firm has a market capitalization of $226.98 billion, a price-to-earnings ratio of 38.41, a P/E/G ratio of 3.83 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter last year, the firm posted $5.15 EPS. The business’s quarterly revenue was down 1.4% on a year-over-year basis. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.